(Q39920504)

15 September 2017

title

From wild fowl to stalking horses: Alchemy in chemotherapy.Fifth annual David A. Karnofsky memorial lecture (English)

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

From wild fowl to stalking horses: alchemy in chemotherapy. Fifth annual David A. Karnofsky Memorial Lecture (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A163674

16 May 2022

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

1

Burchenal JH

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 April 1975

1 reference

full work available at URL

15 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

1 reference

15 September 2017

volume

35

1 reference

15 September 2017

issue

4

1 reference

15 September 2017

page(s)

1121-1135

1 reference

A METHYLHYDRAZINE DERIVATIVE IN HODGKIN'S DISEASE AND OTHER MALIGNANT NEOPLASMS. THERAPEUTIC AND TOXIC EFFECTS STUDIED IN 51 PATIENTS.

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197504%2935%3A4%3C1121%3A%3AAID-CNCR2820350416%3E3.0.CO%3B2-B

5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)—A new antitumor agent with activity against malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197504%2935%3A4%3C1121%3A%3AAID-CNCR2820350416%3E3.0.CO%3B2-B

Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197504%2935%3A4%3C1121%3A%3AAID-CNCR2820350416%3E3.0.CO%3B2-B

PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197504%2935%3A4%3C1121%3A%3AAID-CNCR2820350416%3E3.0.CO%3B2-B

Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197504%2935%3A4%3C1121%3A%3AAID-CNCR2820350416%3E3.0.CO%3B2-B

Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197504%2935%3A4%3C1121%3A%3AAID-CNCR2820350416%3E3.0.CO%3B2-B

Radiation therapy for intracranial lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197504%2935%3A4%3C1121%3A%3AAID-CNCR2820350416%3E3.0.CO%3B2-B

21 January 2018

3

27

2565

Bernard

1967

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

David A. Karnofsky memorial lecture. Thoughts on chemical therapy

16 May 2022

7

26

737

Billroth

1970

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

[Clinical experiences with sarcolysin in neoplastic diseases]

16 May 2022

8

68

1128

Blokhin

1958

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Tumour inhibitory effects of a new class of cytotoxic agents: methylhydrazine derivatives

16 May 2022

10

19

130

Bollag

1963

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

11

30

2572

Bonadonna

1970

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

[Effect of a cyclic nitrogen mustard-phosphamidester on experimentally induced tumors in rats; chemotherapeutic effect and pharmacological properties of B 518 ASTA.]

16 May 2022

12

83

453

Brock

1958

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects

16 May 2022

13

191

1114

Broome

1961

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance

16 May 2022

series ordinal

14

volume

118

0 references

MITHRAMYCIN IN THE TREATMENT OF DISSEMINATED TESTICULAR NEOPLASMS

15

272

111

Brown

1965

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Chemotherapy and radiotherapy--competitors or partners?

16 May 2022

19

22

790

Burchenal

1968

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

New cancer chemotherapeutic agents

16 May 2022

22

30

1639

Burchenal

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Single and combination nonhormonal chemotherapy in breast cancer

16 May 2022

30

30

1543

Carter

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Treatment of Acute Myeloblastic Leukemia1

16 May 2022

34

1098

Clarkson

1973

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Doxorubicin in disseminated osteosarcoma

16 May 2022

38

221

1132

Cortes

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

A decade of combination chemotherapy of advanced Hodgkin's disease

16 May 2022

40

30

1495

DeVita

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Rhabdomyosarcoma of head and neck in children. Combination treatment by surgery, irradiation, and chemotherapy.

16 May 2022

47

31

26

Donaldson

1973

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

Klinische Wochenschrift

52

41

329

Ehrlich

1904

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Studies on Condensed Pyrimidine Systems. IX. The Synthesis of Some 6-Substituted Purines

16 May 2022

54

74

411

Elion

1952

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

The Synthesis of 6-Thioguanine

16 May 2022

55

77

1676

Elion

1955

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Hematological effects of the alkylating agents

16 May 2022

59

68

826

Elson

1958

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

British Journal of Pharmacology

16 May 2022

62

6

185

Falco

1951

0 references

Chemotherapy in the treatment of leukemia and Wilms' tumor

65

198

826

Farber

1966

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

16 May 2022

66

238

787

Farber

1948

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Myleran in chronic myeloid leukaemia; results of treatment

16 May 2022

74

264

208

Galton

1953

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma.

16 May 2022

75

1172

Galton

1955

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Treatment of adult acute leukemia with arabinosylcytosine and thioguanine

16 May 2022

76

23

1019

Gee

1969

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

A study of “total therapy” of acute lymphocyticleukemia in children

16 May 2022

77

72

399

George

1968

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Multidisciplinary treatment of embryonal rhabdomyosarcoma in children

16 May 2022

79

35

677

Ghavimi

1975

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides

16 May 2022

81

103

409

Gilman

1946

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Eradication Of Leukaemic Cells (L1210) by Methotrexate and Methotrexate Plus Citrovorum Factor

16 May 2022

83

212

1548

Goldin

1966

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Influence of carbamic esters (urethanes) on experimental animal tumors.

16 May 2022

86

157

500

Haddow

1946

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Myleran in chronic myeloid leukaemia; chemical constitution and biological action

16 May 2022

87

264

207

Haddow

1953

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol)

16 May 2022

88

33

1491

Haghbin

1974

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

16 May 2022

90

179

663

Heidelberger

1957

0 references

Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2'-deoxyuridine on transplanted tumors

91

97

470

Heidelberger

1958

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

SYNTHESES OF 5-TRIFLUOROMETHYLURACIL AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE.

16 May 2022

92

7

1

Heidelberger

1964

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Studies on analogs of purines and pyrimidines

16 May 2022

97

52

1318

Hitchings

1950

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

The chemistry and biochemistry of purine analogs

16 May 2022

98

60

183

Hitchings

1954

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Chemotherapy of acute lymphocytic leukemia of childhood

16 May 2022

100

30

1480

Holland

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Treatment of clinically localized Ewing's sarcoma with radiotherapy and combination chemotherapy

16 May 2022

102

30

1522

Hustu

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

NITROGEN MUSTARD THERAPY

103

132

263

Jacobson

1946

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Recent advances in the chemotherapy of metastatic osteogenic sarcoma

16 May 2022

105

30

1627

Jaffe

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

The Synthesis of Potential Anticancer Agents. XXXVI. N-Nitrosoureas.1 II. Haloalkyl Derivatives

16 May 2022

110

9

892

Johnson

1966

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use

16 May 2022

111

87

477

Karnofsky

1951

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine

16 May 2022

113

109

251

Kaufman

1961

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

THERAPEUTIC ANTIVIRAL ACTION OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE IN HERPES SIMPLEX KERATITIS.

16 May 2022

114

145

585

Kaufman

1964

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

Molecular Pharmaceutics

116

7

117

Kessel

0 references

Molecular Pharmacology

117

5

481

Kessel

1969

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum

16 May 2022

118

98

565

Kidd

1953

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Wilms tumor: a report of 45 cases and an analysis of 1,351 cases reported in the world literature from 1940 to 1958

16 May 2022

120

81

633

Klapproth

1959

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Chemotherapy of gestational choriocarcinoma

16 May 2022

126

30

1517

Lewis

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Management of choriocarcinoma and related tumors of uterus and testis

16 May 2022

127

45

661

Li

1961

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Effects of combined drug therapy on metastatic cancer of the testis

16 May 2022

129

174

1291

Li

1960

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

IMMUNOLOGIC RESPONSES OF HEALTHY VOLUNTEERS RECEIVING AZATHIOPRINE (IMURAN)

16 May 2022

132

27

102

Maibach

1965

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI

16 May 2022

135

105

451

Mashburn

1964

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

METHYL-HYDRAZINE IN TREATMENT OF HODGKIN'S DISEASE AND VARIOUS FORMS OF HAEMATOSARCOMA AND LEUKAEMIA

16 May 2022

136

1077

Mathé

1963

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

The comparative effects of five polyfunctional alkylating agents on the rat fetus, with additional notes on the chick embryo

16 May 2022

140

68

762

Murphy

1958

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Malignant lymphoma involving the jaw in African children: treatment with Methotrexate

16 May 2022

143

16

616

Oettgen

1963

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Treatment of lymphosarcoma in the dog with L-asparaginase

16 May 2022

147

20

1066

Old

1967

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Leukaemia treated with urethane, compared with deep x-ray therapy.

16 May 2022

148

677

Paterson

1946

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Hodgkin's disease. Combined clinical staff conference at the National Institutes of Health

16 May 2022

151

67

424

Perry

1967

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Proceedings: Disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy

16 May 2022

158

33

384

Rosen

1974

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Combination chemotherapy and radiotherapy for Hodgkin's disease

16 May 2022

159

30

1505

Rosenberg

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Antagonist for pteroylglutamic acid

16 May 2022

170

69

2567

Seeger

1947

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia

16 May 2022

172

92

628

Shay

1953

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Antitumor activity of triazenoimidazoles

16 May 2022

173

11

674

Shealy

1962

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer

16 May 2022

177

12

1248

Sullivan

1959

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity

16 May 2022

180

6

142

Sykes

1953

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

16 May 2022

183

20

333

Tan

1967

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Intrathecal amethopterin in neurological manifestations of leukemia

16 May 2022

191

101

279

Whiteside

1958

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

Chemotherapy of Burkitt's lymphoma.

16 May 2022

198

30

1534

Ziegler

1972

1 reference

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

https://api.crossref.org/works/10.1002/1097-0142(197504)35:4%3C1121::AID-CNCR2820350416%3E3.0.CO;2-B

16 May 2022

Identifiers

10.1002/1097-0142(197504)35:4<1121::AID-CNCR2820350416>3.0.CO;2-B

1 reference

15 September 2017

1 reference